Company: HCTI
Filing Date: 2025-11-28
Form Type: S-3
Source: 0001213900-25-115888
Chunk: 25

Company: Healthcare Triangle, Inc.
Filing Date: 2025-11-28
Form: S-3
Chunk 25
---
 or other securities. In addition, the issuance of the Conversion Shares and future equity offerings and other issuances of our Common Stock or other securities may adversely affect our Common Stock price.

In order to raise additional capital, we may in
the future offer additional shares of our Common Stock or other securities convertible into or exchangeable for our Common Stock at prices
that may not be the same as the price per share as prior issuances of Common Stock. We may not be able to sell shares or other securities
in any other offering at a price per share that is equal to or greater than the price per share previously paid by investors, and investors
purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which
we sell additional shares of our Common Stock or securities convertible into Common Stock in future transactions may be higher or lower
than the prices per share for previous issuances of Common Stock or securities convertible into Common Stock paid by certain investors.
You will incur dilution upon exercise of any outstanding stock options, warrants or upon the issuance of shares of Common Stock under
our equity incentive programs. In addition, the issuance of the Conversion Shares and any future sales of a substantial number of shares
of our Common Stock in the public market, or the perception that such sales may occur, could adversely affect the price of our Common
Stock. We cannot predict the effect, if any, that market sales of those shares of Common Stock or the availability of those shares for
sale will have on the market price of our Common Stock.

Substantial future sales of shares of our Common Stock could cause the market price of our Common Stock to decline.

We expect that significant additional capital
will be needed in the near future to continue our planned operations. Sales of a substantial number of shares of our Common Stock in the
public market, or the perception that these sales might occur, could depress the market price of our Common Stock and could impair our
ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that such sales may have
on the prevailing market price of our shares.

We have financed our operations, and we expect
to continue to finance our operations, acquisitions, if any, and the development of strategic relationships by issuing equity, warrants
and/or convertible securities, which could significantly reduce the percentage ownership of our existing stockholders. Further, any additional
financing that we secure may require the granting of rights, preferences or privileges senior to, or pari